Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency

ADAM17 (a disintegrin and metalloproteinase 17)/TACE (TNFα converting enzyme) has emerged as a potential therapeutic target in colorectal cancer (CRC) and other cancers, due in part to its role in regulating various tumor cell surface proteins and growth factors and cytokines in the tumor microenvir...

Descripción completa

Detalles Bibliográficos
Autores principales: Dosch, Joseph, Ziemke, Elizabeth, Wan, Shanshan, Luker, Kathryn, Welling, Theodore, Hardiman, Karin, Fearon, Eric, Thomas, Suneetha, Flynn, Matthew, Rios-Doria, Jonathan, Hollingsworth, Robert, Herbst, Ronald, Hurt, Elaine, Sebolt-Leopold, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630314/
https://www.ncbi.nlm.nih.gov/pubmed/29029414
http://dx.doi.org/10.18632/oncotarget.17780

Ejemplares similares

Ejemplares similares